Opciones terapéuticas para el tratamiento antifúngico en el paciente crítico

Aguado, 2011, Recomendaciones sobre el tratamiento de la candidiasis invasiva yotras infecciones por levaduras de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) Actualización 2011, Enferm Infecc Microbiol Clin, 29, 345, 10.1016/j.eimc.2011.01.008 Alvarez-Lerma, 2005, Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients, J Chemother, 17, 417, 10.1179/joc.2005.17.4.417 Barrett, 2003, A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations, Clin Ther, 25, 1295, 10.1016/S0149-2918(03)80125-X Bergner, 2006, Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800mg, Nephrol Dial Transplant, 21, 1019, 10.1093/ndt/gfi284 Carrillo-Muñoz, 2006, Antifungal agents: mode of action in yeast cells, Rev Esp Quimioter, 19, 130 Cornely, 2007, Caspofungin for the treatment of less common forms of invasive candidiasis, J Antimicrob Chemother, 60, 363, 10.1093/jac/dkm169 Cornely, 2007, Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia, N Engl J Med, 356, 348, 10.1056/NEJMoa061094 DiNubile, 2007, Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial, J Crit Care, 22, 237, 10.1016/j.jcrc.2006.11.004 Dupont, 2002, Overview of the lipid formulations of amphotericin B, J Antimicrob Chemother, 49, 31, 10.1093/jac/49.suppl_1.31 Dupont, 2009, Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B, Crit Care, 13, R159, 10.1186/cc8117 Espinel-Ingroff, 2011, In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same?, Enferm Infecc Microbiol Clin, 29, 3, 10.1016/S0213-005X(11)70002-7 Fluckiger, 2006, Treatment options of invasive fungal infections in adults, Swiss Med Wkly, 136, 447 Fortún, 2011, Recomendaciones sobre el tratamiento de la enfermedad fúngica invasiva por Aspergillus spp. y otros hongos filamentosos de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2011, Enferm Infecc Microbiol Clin, 29, 435, 10.1016/j.eimc.2011.01.010 Garey, 2006, Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multiinstitutional study, Clin Infect Dis, 43, 25, 10.1086/504810 GarnachoMontero, 2005, Recomendaciones terapéuticas para infecciones fúngicas en el paciente crítico no neutropénico. Conferencia de consenso. Conclusiones, Med Intensiva, 3, 43 Guery, 2009, Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II, Treatment Intensive Care Med, 35, 206, 10.1007/s00134-008-1339-6 Herbrecht, 2002, Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis, N Engl J Med, 347, 408, 10.1056/NEJMoa020191 Ibrahim, 2000, The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting, Chest, 118, 146, 10.1378/chest.118.1.146 Ito, 2005, Treatment of Candida infections with amphotericin B lipid complex, Clin Infect Dis, 40, S384, 10.1086/429330 Kett, 2011, Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis, Crit Care, 15, R253, 10.1186/cc10514 Kuhn, 2002, Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins, Antimicrob Agents Chemother, 46, 1773, 10.1128/AAC.46.6.1773-1780.2002 Kullberg, 2005, Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial, Lancet, 366, 1435, 10.1016/S0140-6736(05)67490-9 Kullberg, 2011, European expert opinion on the management of invasive candidiasis in adults, Clin Microbiol Infect, 17, 1, 10.1111/j.1469-0691.2011.03615.x Kuse, 2007, Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial, Lancet, 369, 1519, 10.1016/S0140-6736(07)60605-9 Leroy, 2009, Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006), Crit Care Med, 37, 1612, 10.1097/CCM.0b013e31819efac0 Limper, 2011, An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients, Am J Respir Crit Care Med, 183, 96, 10.1164/rccm.2008-740ST Lutsar, 2003, Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients, Clin Infect Dis, 37, 728, 10.1086/377131 Maertens, 2004, Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy, Clin Infect Dis, 39, 1563, 10.1086/423381 Marr, 2004, Combination antifungal therapy: where are we now, and where are we going?, Oncology (Williston Park), 18, 24 Marr, 2004, Combination antifungal therapy for invasive aspergillosis, Clin Infect Dis, 39, 797, 10.1086/423380 Mora-Duarte, 2002, Comparison of caspofungin and amphotericin B for invasive candidiasis, N Engl J Med, 347, 2020, 10.1056/NEJMoa021585 Morrell, 2005, Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality, Antimicrob Agents Chemother, 49, 3640, 10.1128/AAC.49.9.3640-3645.2005 Muñoz, 2005, Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital, J Antimicrob Chemother, 55, 188, 10.1093/jac/dkh532 Ortega, 2011, Candida species bloodstream infection: epidemiology and outcome in a single institution from 1991 to 2008, J Hosp Infect, 77, 157, 10.1016/j.jhin.2010.09.026 Ortega, 2010, Candida spp. bloodstream infection: influence of antifungal treatment on outcome, J Antimicrob Chemother, 65, 562, 10.1093/jac/dkp495 Ostrosky-Zeichner, 2003, Voriconazole salvage treatment of invasive candidiasis, Eur J Clin Microbiol Infect Dis, 22, 651, 10.1007/s10096-003-1014-3 Pachón, 2006, Tratamiento de las infecciones fúngicas invasivas, Enferm Infecc Microbiol Clin, 24, 254, 10.1016/S0213-005X(06)73772-7 Pappas, 2009, Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America, Clin Infect Dis, 48, 503, 10.1086/596757 Pappas, 2004, Guidelines for treatment of candidiasis, Clin Infect Dis, 38, 161, 10.1086/380796 Pappas, 2007, Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis, Clin Infect Dis, 45, 883, 10.1086/520980 Pemán, 2005, Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in, Spain Eur J Clin Microbiol Infect Dis, 24, 23, 10.1007/s10096-004-1267-5 Pemán, 2006, Voriconazole in the management of nosocomial invasive fungal infections, Ther Clin Risk Management, 2, 1 Perfect, 2003, Voriconazole treatment for less-common, emerging, or refractory fungal infections, Clin Infect Dis, 36, 1122, 10.1086/374557 Phillips, 1997, Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group, Eur J Clin Microbiol Infect Dis, 16, 337, 10.1007/BF01726360 Reboli, 2007, Anidulafungin versus fluconazole for invasive candidiasis, N Engl J Med, 356, 2472, 10.1056/NEJMoa066906 Reboli, 2011, Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome, BMC Infect Dis, 11, 261, 10.1186/1471-2334-11-261 Rex, 1994, A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute, N Engl J Med, 331, 1325, 10.1056/NEJM199411173312001 Rodríguez-Tudela, 2007, Correlation of the MIC and Dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidaemia, Antimicrob Agents Chemother, 51, 3599, 10.1128/AAC.00296-07 Shorr, 2007, Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia, Crit Care Med, 35, 1077, 10.1097/01.CCM.0000259379.97694.00 Singh, 2006, Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study, Transplantation, 81, 320, 10.1097/01.tp.0000202421.94822.f7 Troke P, Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, et al. Voriconazole (VCR) therapy (Rx) in 86 patients (pts) with CNS aspergillosis (CNSA): a retrospective analysis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Il 476. 2003. Vazquez, 2006, a novel echinocandin, Clin Infect Dis, 43, 215, 10.1086/505204 Walsh, 2004, Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia, N Engl J Med, 351, 1391, 10.1056/NEJMoa040446 Wingard, 1999, Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis, Clin Infect Dis, 29, 1402, 10.1086/313498 Zaragoza, 2006, Voriconazol en UCI: ¿cuáles son sus indicaciones, ventajas, precauciones y contraindicaciones reales?, Med Intensiva, 4, S11 Zaragoza, 2007, Diagnostic and therapeutic approach to fungal infections in critical care settings: different options but the same strategy, J Invasive Fungal Infect, 1, 50